Abstract
The pharmacokinetics of lopinavir/ritonavir (LPV/RTV) 300 mg/m twice daily and efavirenz (EFV) 350 mg/m once daily were evaluated in HIV-infected children. The minimum concentrations for LPV contained values above the target range, and the estimated minimum concentrations for EFV contained values below the range. Our data support the current LPV/RTV dose, but EFV 350 mg/m may not be sufficient.
Publication types
-
Clinical Trial
-
Research Support, N.I.H., Extramural
MeSH terms
-
Adolescent
-
Alkynes
-
Anti-HIV Agents / administration & dosage
-
Anti-HIV Agents / pharmacokinetics*
-
Anti-HIV Agents / therapeutic use
-
Benzoxazines / administration & dosage
-
Benzoxazines / pharmacokinetics*
-
Benzoxazines / therapeutic use
-
Child
-
Child, Preschool
-
Cyclopropanes
-
Drug Interactions
-
Drug Therapy, Combination
-
Female
-
HIV Infections / drug therapy*
-
Humans
-
Lopinavir
-
Male
-
Pyrimidinones / administration & dosage
-
Pyrimidinones / pharmacokinetics*
-
Pyrimidinones / therapeutic use
-
Ritonavir / administration & dosage
-
Ritonavir / pharmacokinetics*
-
Ritonavir / therapeutic use
Substances
-
Alkynes
-
Anti-HIV Agents
-
Benzoxazines
-
Cyclopropanes
-
Pyrimidinones
-
Lopinavir
-
efavirenz
-
Ritonavir